UK Markets open in 5 hrs 58 mins
  • NIKKEI 225

    26,756.46
    -44.52 (-0.17%)
     
  • HANG SENG

    26,605.74
    +73.16 (+0.28%)
     
  • CRUDE OIL

    45.11
    -0.17 (-0.38%)
     
  • GOLD FUTURES

    1,828.90
    +3.20 (+0.18%)
     
  • DOW

    29,883.79
    +59.87 (+0.20%)
     
  • BTC-GBP

    14,241.56
    -148.02 (-1.03%)
     
  • CMC Crypto 200

    373.16
    +8.24 (+2.26%)
     
  • Nasdaq

    12,349.37
    -5.74 (-0.05%)
     
  • ^FTAS

    3,651.32
    +37.15 (+1.03%)
     

Prosecutor pressed charges against a member of Orion’s Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion

Orion Oyj
·1-min read

ORION CORPORATION STOCK EXCHANGE RELEASE 29 OCTOBER 2020 at 19.00 EET

Prosecutor pressed charges against a member of Orion’s Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion

In accordance with the rules of the stock exchange, Orion Corporation discloses the following information:

It has come to the attention of Orion Corporation that Ari Lehtoranta, a member of Orion’s Board of Directors, has been charged in a securities markets case concerning suspected disclosure offence. According to the information Orion has, the matter is related to Mr. Lehtoranta’s operations as the CEO of Nokian Tyres Plc in 2015-2016. According to the information Orion has, Mr. Lehtoranta has denied any involvement in criminal activity.

The suspected offence is not related to Orion and Orion will not comment on the matter.

Orion Corporation

Timo Lappalainen
President and CEO

Olli Huotari
SVP, Corporate Functions


Contact person:
Terhi Ormio, VP, Communications
tel. +358 10 426 4646

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.